



ARECOR LIMITED

("Arecor" or "the Company")

ARECOR JOINS ELITE INVESTOR ROADSHOW TO CHINA

"Arecor has joined the London Stock Exchange Group's latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong, between 15th - 18th October 2018"

Cambridge, UK., 15 October 2018: Arecor Limited ("the Company"), the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce that the Company has joined the London Stock Exchange Group ("LSEG")'s latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong, in addition to meeting separately with key pharmaceutical partners in China.

Dr Sarah Howell, Chief Executive Officer at Arecor, commented: *"With China a fast-growing and increasingly important region in the global biopharmaceutical economy, Arecor's visit to Shenzhen and Hong Kong is both timely and important. Not only does the country offer huge opportunities for companies such as Arecor, in terms of investment and partnering, but it is itself facing significant unmet medical needs - particularly in the diabetes space. We are very excited by the opportunities available in China and its strategic fit with our diabetes portfolio in what is the world's second largest pharmaceutical market. The Elite programme and the credibility that comes from the LSE has been a great help in getting the right investor contacts in China."*

For more information, please contact:

Arecor Limited

www.arecor.com

Dr Sarah Howell, Chief Executive

Tel: +44 (0) 1223 426 060

Peckwater PR

Tarquin Edwards

tarquin.edwards@peckwaterpr.co.uk

Tel: +44 (0) 7879 458 364



About Arecor

Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides.

Arecor's product portfolio also includes:

- Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
- Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
- Stable aqueous glucagon for emergency and artificial pancreas use, and
- A series of undisclosed pre-clinical programmes.

In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

www.arecor.com

About Arestat™

Arecor has significant experience and a proven track record in applying the Arestat™ formulation technology platform to deliver superior biopharmaceutical product profiles across a broad range of proteins, peptides and vaccines.

About Arecor's Patent Portfolio

Arecor's technology is protected by 28 patent families, including 26 granted patents. Arecor has been exploiting its technology in partnerships with pharmaceutical companies, successfully developing superior product profiles, including stable high-concentration antibodies with low viscosity, reformulations of lyophilised or freeze-dried products into stable liquids or stable vaccines that can be used outside the cold chain.